IBI363

Multispecific antibody

Also known as TAK-928

Phase 3underway

Evidence outlook · registrational

Non-Small Cell Lung Cancer: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-11-01.

Also in development:Colorectal Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Colorectal Cancer
Non-Small Cell Lung Cancer
Phase 2 (10)
Non-Small Cell Lung Cancer
NCT07402070 · Innovent Biologics (Suzhou) Co. Ltd.
2026-02-04 – 2030-12-31 · Resectable Stage II-III Non-small Cell Lung Cancer
What this study did
NCT07408635 · Shanghai Pulmonary Hospital, Shanghai, China
2026-01-07 – 2030-01-06 · Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
What this study did
NCT06620822 · Shanghai Pulmonary Hospital, Shanghai, China
2024-09-30 – 2027-09-30 · Non Small Cell Lung Cancer
What this study did
NCT06281678 · Innovent Biologics (Suzhou) Co. Ltd.
2024-04-08 – 2026-12-31 · Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Renal Cell Cancer
What this study did
Other / comorbidity
NCT07289048 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-12-20 – 2028-12-30 · SCLC,Extensive Stage
What this study did
NCT06081920 · Innovent Biologics (Suzhou) Co. Ltd.
2023-10-19 – 2028-10-19 · Melanoma
What this study did
NCT07325630 · Zhejiang Cancer Hospital
2025-11-03 – 2027-12-31 · IBI363 + Chemotherapy
What this study did
Phase 1/2 (4)
Other / comorbidity
NCT07307053 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-01-01 – 2031-01-31 · Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors
What this study did
NCT07361991 · The First Affiliated Hospital of Zhengzhou University
2026-03 – 2030-09 · Advan'ce'd, Advanced
What this study did
NCT07342725 · Ruijin Hospital
2026-01-01 – 2028-12-31 · Pancreatic Cancer Metastatic
What this study did
NCT06081907 · Hunan Province Tumor Hospital
2023-12-25 – 2028-09-01 · Advanced Solid Tumor
What this study did
Phase 1 (5)
Colorectal Cancer
NCT06717880 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2023-07-28 – 2026-07-31 · Advanced Malignancies
What this study did
Other / comorbidity
NCT05460767 · Innovent Biologics (Suzhou) Co. Ltd.
2022-08-31 – 2027-06-30 · Solid Tumors or Lymphoma
What this study did
NCT06468098 · Innovent Biologics (Suzhou) Co. Ltd.
2024-06-15 – 2026-12-31 · Advanced Malignancies
What this study did
NCT06610799 · Xiangdong Cheng
2024-10-15 – 2026-12-31 · IBI363 + Chemotherapy
What this study did
NCT05290597 · Innovent Biologics (Suzhou) Co. Ltd.
2022-08-22 – 2026-12-31 · Solid Malignancies or Lymphomas
What this study did

Competitive landscape

Other PD-1 x IL-2Rα (IL2RA) drugs

REGN10597. Compare all 2 PD-1 x IL-2Rα (IL2RA) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IBI363: this drugPhase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
REGN10597
Phase 1/2(overall)
Multispecific antibodyPD-1 x IL-2Rα (IL2RA)
not yet graded(overall)
No reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IBI363 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (5)
November 2026 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-30 · NCT07122687 · CT.gov ↗
What to watch
December 2026 (4)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2026-12-01 · NCT06081907 · CT.gov ↗
What to watch
Phase 1Solid Tumors or LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05460767 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07402070 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2026-12-31 · NCT06797297 · CT.gov ↗
What to watch
2027 (2)
December 2027 (2)
Phase 2SCLC,Extensive StageNot yet recruiting
Est. primary completion 2027-12-30 · NCT07289048 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer MetastaticNot yet recruiting
Est. primary completion 2027-12-31 · NCT07342725 · CT.gov ↗
What to watch
2028 (5)
June 2028 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-06 · NCT07408635 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Advan'ce'd, AdvancedNot yet recruiting
Est. primary completion 2028-09 · NCT07361991 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2028-10-19 · NCT06081920 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2028-10-31 · NCT07722494 · CT.gov ↗
What to watch
November 2028 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-01 · NCT07217301 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 1/2Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2029-01-31 · NCT07307053 · CT.gov ↗
What to watch

See the full readout calendar ↗